Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Primary Myelofibrosis 9Leukemia 7Myeloproliferative Disorders 6Polycythemia Vera 4Leukemia, Myeloid, Acute 4Thrombocytosis 3Thrombocythemia, Essential 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Multiple Myeloma 3Breast Neoplasms 3Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hematologic Diseases 2Carcinoma, Non-Small-Cell Lung 2Bone Marrow Diseases 2Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Disorder 1Recurrence 1Preleukemia 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Peripheral Blood Stem Cell Transplantation 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1

Interventions

Cyclophosphamide 2ruxolitinib 1fludarabine phosphate 1fludarabine 1etoposide phosphate 1brincidofovir 1Vincristine 1Raltegravir Potassium 1Prednisone 1Etoposide 1Doxorubicin 1Daclizumab 1Bortezomib 1B3(Fv)-PE38KDEL recombinant immunotoxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia-Lymphoma, Adult T-Cell × ruxolitinib × Clear all
NCT01712659 2023-01-10

Ruxolitinib for Adult T-Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
19 enrolled 17 charts
LymphoidOther hematologic neoplasm

Leukemia, T-Cell, Leukemia-Lymphoma, Adult T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡